Unicycive Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Unicycive Therapeutics, Inc. (UNCY) on June 9, 2025. The record date for the meeting was April 30, 2025. The company is incorporated in Delaware and trades on the Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes rather than financial performance.
Material Changes and Voting Results
Approximately 69.70% of the total voting power (88,440,393 votes) was represented at the meeting. The following matters were approved:
- Director Elections: All four nominees were elected. Dr. Gaurav Aggarwal and Dr. Shalabh Gupta received the highest support, while Dr. Sandeep Laumas and D. Sarawati Kenkare-Mitra received significant "Withhold" votes (7,888,833 and 11,935,993 respectively).
- Independent Auditor: Stockholders ratified the appointment of Grassi & Co. CPAs, P.C. for the fiscal year ending December 31, 2025.
- Reverse Stock Split: The proposal to implement a reverse stock split was approved by stockholders.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on operational outlook, specific risks, or contingencies beyond the standard disclosure of the voting results.
Investor Verification Checklist
- Verify the specific ratio of the approved Reverse Stock Split in subsequent filings or press releases.
- Review the Definitive Proxy Statement (filed April 30, 2025) for details on the rationale behind the reverse stock split and the significant withhold votes for two directors.
- Confirm the effective date of the reverse stock split and its impact on share count and trading price.
- Monitor upcoming financial reports for the fiscal year ending December 31, 2025, to assess the company's liquidity and operational status.